Our approach has been validated in cells, animals, and in the clinic.
With over 20 peer review journals, multiple case studies, and success advancing lead candidates through clinical trials; we’re confident in our approach.
We invite you to read more about our technology in publications, cases studies, news and more.
We’re answering questions across the entire development process.
From identifying new targets to optimizing compounds for toxicity or efficacy – our platform evaluates preclinical R&D as a whole. Our holistic view enables us to share data and insights across the drug development pipeline, leading to informed and expansive insights.
Currently we’ve built in over 14 different algorithms into the platform and we’re constantly adding in more.